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Abstract The immunosuppressive cyclic nonapeptide cyclolino-
peptide A inhibits calcium-dependent, but not calcium-indepen-
dent, activation of T lymphocytes comparably to the actions of 
cyclosporin A and FK506. The concentration required for 
complete inhibition, however, is 10 times higher than that of 
cyclosporin A. In addition, we demonstrate that calcineurin, a 
phosphatase which plays an important role in T lymphocyte 
signalling, is inhibited in vitro by cyclolinopeptide A by a 
mechanism dependent on the peptidyl-prolyl cis-trans isomerase 
(PPIase) cyclophilin A but not FKBP12. Direct binding of 
cyclolinopeptide A to cyclophilin A was confirmed using 
tryptophan fluorescence studies and PPIase assays. These results 
represent a third example of the production of a natural product 
that neutralises calcineurin by a mechanism dependent on the 
primary binding to a PPIase. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cyclolinopeptide A (CLA) is a naturally occurring cyclic 
nonapeptide isolated from linseed oil [1] with the sequence: 
3 4 5 6 
Pro - Phe - Phe - Leu \ 
1 He 7 
Pro - Val - Leu - lie / 
2 1 9 8 
It is one of a much larger group of cyclic oligopeptides re-
ported to have immunosuppressive activities [2]. It was found 
that CLA inhibited primary and secondary humoral responses 
in CBA mice and that cellular immune responses were down-
regulated in vivo suggesting that CLA was comparable to 
cyclosporin A (CsA) in its immunosuppressive activity [3]. 
CsA is an immunosuppressive hydrophobic undecapeptide de-
rived from the fungus Tolypocladium inflation [4] used clini-
cally to prevent transplant rejection and to treat autoimmune 
disease. The structurally dissimilar macrolide FK506 derived 
from Streptomyces tsukubaenis [5] inhibits T lymphocyte acti-
vation at concentrations 2-3 orders of magnitude lower than 
CsA. However, both agents block calcium-dependent induc-
tion of T lymphocyte activation within the first few hours 
after mitogen stimulus, whilst neither drug affects early 
changes induced in the absence of calcium, most notably those 
that occur in response to the activation of protein kinase C by 
phorbol esters [6]. 
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The presence of a pair of cis-linked proline residues suggests 
that CLA might resemble CsA or FK506 in targeting the 
cyclophilin or the FKBP12 family of peptidyl-prolyl cis-trans 
isomerases (PPIases). Once CsA and FK506 bind to their 
respective protein, PPIase activity is abolished [7]. Cyclophil-
ins and FKBPs are sequence-unrelated families of proteins 
that accelerate in vitro protein folding and have been postu-
lated to have chaperone and membrane trafficking properties 
in vivo [8]. CSA and FK506 become active once complexed 
with the PPIases, binding to calcineurin and inhibiting its 
phosphatase activity [9]. Calcineurin plays a key role in ini-
tiating T lymphocyte activation by dephosphorylating the nu-
clear factor of activated T cells (NF-AT) which in turn trans-
locates from the cytoplasm to the nucleus, where it is required 
for the induction of transcription of m R N A for interleukin-2 
and other cytokines [10]. 
In this communication, we show that C L A and its sulpho-
nated analogue MC-172 mirror the action of CsA through 
their inhibition of T cell activation by binding to cyclophilin, 
inhibiting its PPIase activity and in turn creating a composite 
site for the interaction and inhibition of calcineurin. 
2. Materials and methods 
2.1. Drugs and proteins 
For cell culture assays, cyclosporin A (Sandoz Ltd, Basle, Switzer-
land) was dissolved in ethanol/Tween 80 as described previously [11] 
and diluted to 100 uM in Eagle's minimal essential media (EMEM). 
The synthesis of the linear CLA precursor with the sequence Leu-Ile-
Ile-Leu-Val-Pro-Pro-Phe-Phe and the cyclic nonapeptide CLA was 
shortly described in [3]. The synthesis of the sulphonated analogue 
of CLA, MC-172, with the sequence c-(Val-Pro-Pro-Pne-Phe[S03Na]-
Leu-Ile-Ile-Leu) is described in [12]. CLA, linear CLA and MC-172 
were dissolved as for CsA. For all other assays, these peptides were 
dissolved solely in ethanol. FK506 (Fujisawa Pharmaceuticals Ltd., 
Osaka, Japan) and rapamycin (Wyeth-Ayerst Res. Labs., Princeton, 
NJ, USA) were dissolved in ethanol. Concanavalin A (Sigma Aldrich 
Co. Ltd., Poole, UK) was dissolved in EMEM and added to cultures 
to give a final concentration of 5 n.g/ml. 12-O-Tetradecanoyl phorbol-
13-acetate (TPA, Sigma) was dissolved in ethanol and added to cul-
tures to give a final concentration of 10 nM. The calcineurin-specific 
peptide DLDVPIPGRFDRRVSVAAE was synthesised by Chris Ko-
walczyk, Interdisciplinary Research Centre, School of Biological Sci-
ences, University of Sussex, Brighton, UK. 
Cyclophilin A was purified from porcine kidney using gel filtration 
(FPLC, Superose-12, Pharmacia Biotech, Uppsala, Sweden) and cat-
ion exchange chromatography (Fast Flow Sepharose, Sigma) and 
suspended in 20 mM MES-NaOH pH 6.5. Human recombinant 
FKBP12 [13] was expressed in Escherichia coli strain XA90 and pu-
rified by gel filtration and cation exchange techniques before suspen-
sion in 20 mM MES-NaOH pH 6.0. 
2.2. Preparation and activation of lymphocytes 
Lymphocytes were prepared from heparinised porcine blood using 
Hypaque-Ficoll gradients and cultured at 2X 106/ml in EMEM sup-
plemented with 5°/i heat-inactivated foetal calf serum and 2 mM glu-
tamine. Activation was assessed by determining the rate of incorpo-
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ration of [35S]methionine (ICN Biomedicals Ltd., Thame, UK) into 
protein at 24 h and [3H]thymidine (Amersham International, Amer-
sham, UK) incorporation into DNA at 48 h. One microcurie of radio-
isotope was added to each of three replicate cultures and left for 4 h at 
37°C before harvesting and incorporation was quantified by liquid 
scintillation counting. 
Activated porcine lymphocyte extracts were prepared by stimulating 
10 ml cultures of porcine lymphocytes (20 X106 cells) with 20 ug/ml 
concanavalin A for 30 min and then lysing the cells in 40 mM MOPS 
pH 7.2, 2 mM benzamidine, 0.5 mM PMSF, 125 mM NaCl, 7 mM (3-
mercaptoethanol, 10 u.g/ml leupeptin, 0.5 mM EDTA and 0.5% NP-
40. The total protein concentration of the cell extracts was determined 
by Bradford assay and adjusted to 10 mg/ml. Extracts were flash-
frozen in liquid nitrogen and stored at — 80°C. 
2.3. PPIase assays and fluorescence spectroscopy 
PPIase activity was determined as described by Fischer et al. [8] 
using 25 |0,M succinyl-AFPF.pNA as substrate. Fluorescence spectros-
copy was based on the procedure described by Handschumacher et al. 
[14] where CsA binding increases the fluorescence intensity of the 
single tryptophan residue of cyclophilin A. In a typical assay, 1 ul 
volumes of CsA or CLA at a final concentration ranging from 10 nM 
to 10 uM were mixed with 300 nM porcine cyclophilin A in 20 mM 
MES-NaOH pH 6.5. Fluorescence was measured in a Perkin-Elmer 
LS3 spectrofluorimeter with an excitation wavelength set at 289 nm 
and the emission spectra recorded between 290 and 385 nm. Values 
shown are the peak fluorescence recorded at 336 nm. 
2.4. Calcineurin assay 
Phosphorylation of the peptide was performed as described by Blu-
menthal et al. [15]. 300 uM of the peptide DLDVPIPGRFDRRVS-
VAAE was phosphorylated by 20 |Xg/ml cAMP-dependent protein 
kinase (Sigma) in a reaction mixture containing 20 mM MOPS pH 
7.2, 2 mM Mg-acetate, 14 mM P-mercaptoethanol, 2 |j,M cAMP, 100 
uM ATP and 300 uM [y-32P]ATP (200-400 cpm/pmol). The reaction 
was started by adding cAMP-dependent protein kinase and the mix-
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Fig. 1. Comparison of the effects of cyclolinopeptide A and cyclo-
sporin A on porcine peripheral lymphocyte activation. Cells were 
activated using the lectin concanavalin A and incubated with cyclic 
cyclolinopeptide A (CLA) (■), linear CLA (•), MC-172 ( ♦ ) and 
CsA ( A ) . A: Protein synthesis was determined by monitoring the 
incorporation of [35S]methionine into protein at 24 h. B: DNA syn-
thesis was assessed by determining the incorporation of 
[3H]thymidine into DNA at 48 h. 
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Fig. 2. Effect of cyclolinopeptide A, cyclosporin A and rapamycin 
on TPA-stimulated porcine lymphocytes. Lymphocytes were acti-
vated with 10 nM TPA and incubated with CLA (■), CsA ( A ) and 
rapamycin (□). Activation was assessed by monitoring the incorpo-
ration of [35S]methionine into protein at 24 h. 
ture was incubated at 30°C for 30 min. Labelled peptide was sepa-
rated from unincorporated ATP by passing the peptide down a 1 ml 
Dowex AG-1 X-8 (Sigma) anion-exchange column. Calcineurin de-
phosphorylation of the peptide was carried out according to the meth-
od of Katagiri et al. [16]. The reaction mixture was incubated at 30°C 
and consisted of 10 uM phosphopeptide (240000 input cpm) in calci-
neurin buffer (50 mM MOPS pH 7.2 with 2 mM Mg-acetate, 2 mM 
MnCl2, 1 |J.M calmodulin (Sigma), 14 mM [5-mercaptoethanol, 100 
uM CaCl2, 2 nM okadaic acid, 0.5 u.M calcineurin (Sigma) and 0.1 
mg/ml bovine serum albumin). The reaction was started by addition 
of the phosphorylated peptide and the reaction mixture was incubated 
for 20 min. Where indicated incubations also contained 1 uM porcine 
kidney cyclophilin A, 1 u.M human recombinant FKBP12, 50 nM 
FK506, 1 |0,M CsA, 10 |0,M CLA or 50 nM rapamycin. In some 
experiments calcineurin and the PPIases were omitted and replaced 
by activated porcine lymphocyte lysates. Dephosphorylation of the 
peptide was carried out in a reaction buffer containing 50 mM 
MOPS pH 7.5, 0.2 mg/ml bovine serum albumin, 3 uM calmodulin, 
2 mM CaCl2, 1 mM EGTA and 10 uM phosphorylated peptide 
(200000 input cpm). 
3. Results and discussion 
Lectins such as concanavalin A crosslink the T lymphocyte 
receptor and activate the calcium-dependent pathway of acti-
vation. CsA and FK506 exhibit their immunosuppressive ac-
tion through the inhibition of this pathway [6]. To determine 
whether cyclolinopeptide A could also inhibit this pathway by 
the same mechanism, we assessed its ability to inhibit porcine 
peripheral lymphocyte activation in comparison to CsA. Fig. 
1 shows the action of CLA, linear C L A and MC-172 on 
protein and D N A synthesis through incorporation of labelled 
methionine and thymidine respectively. Both C L A and M C -
172 were able to inhibit synthesis at concentrations above 
3 |o.M, whilst linear C L A exhibited a lower level of inhibition. 
Thus, sulphonation of one of two Phe residues of C L A in-
creased its solubility, but did not affect its inhibitory action. 
In comparison, CsA inhibits activation at concentrations 
above 300 n M . 
T lymphocytes can also be activated to increase protein 
synthesis through a calcium-independent pathway by addition 
of phorbol esters such as TPA, a response which is insensitive 
to CsA [6]. Like CsA, CLA failed to inhibit protein synthesis 
in TPA-stimulated cells (Fig. 2). 
It has been established that for CsA to inhibit lymphocyte 
activation, it needs to bind the PPIase cyclophilin. In addi-
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Fig. 3. Effect of MC-172 and cyclophilin A on the second phase of 
peptide hydrolysis in the a-chymotrypsin-coupled spectrophotomet-
ric assay. 25 |xM of the peptide Succ-AFPF-pNa in HEPES buffer 
pH 7.5 was incubated with 50 nM porcine kidney cyclophilin A, 10 
u,M MC-172 or 1 uM CsA. Line A: 50 nM porcine kidney cyclo-
philin A+l uM CsA; line B: 50 nM porcine kidney cyclophilin 
A+10 |i.M MC-172; line C: 50 nM porcine kidney cyclophilin A. 
tion, the PPIase activity of cyclophilin is inhibited on binding 
CsA, though it has been shown using synthetic analogues of 
CsA that PPIase activity is not sufficient for the inhibition of 
T cell activation. CLA possesses a pair of proline bonds in the 
cis conformation which is analogous to the MLeu9-MLeu10 
cis linkage in CsA and would therefore be the likely site of 
interaction. We can exploit the inhibition of PPIase activity to 
determine whether cyclophilin A is the intracellular receptor 
for CLA. PPIase assays were carried out according to the 
method of Fischer et al. [8]. The assay relies on the fact 
that a-chymotrypsin can only hydrolyse the chromophore p-
nitroaniline when the X-Pro bond is in the trans conforma-
tion. Approximately 15% of the bond is in cis at equilibrium 
and in the presence of excess a-chymotrypsin, hydrolysis of 
the trans peptide occurs in seconds (first stage) whilst the 
cleavage of the cis peptide is rate-limited by cis-trans isomer-
isation (second phase). PPIases such as cyclophilin catalyse 
the isomerisation. Fig. 3 depicts the second phase of a-chy-
motrypsin hydrolysis and shows that 1 (0.M CsA (line A) and 
10 uM MC-172 (line B) were able to retard peptide hydrolysis 
by inhibiting the PPIase activity of cyclophilin A (line C). 
Using 10 uM CLA gave variable but lower inhibition, prob-
ably due to hydrolysis of the peptide itself by chymotrypsin 
and its poor solubility in the assay buffer. MC-172 and CLA 
and CsA did not inhibit the PPIase activity of FKBP12 (not 
shown). 
It has been shown previously that there is a significant 
modification in the tryptophan fluorescence of cyclophilin 
when titrated with CsA [12]. This modification in fluorescence 
is due to cyclophilin A possessing a single tryptophan in the 
CSA binding pocket and ligation of CsA results in an en-
hancement of fluorescence [17]. This demonstrated a strong 
binding between CsA and cyclophilin. We demonstrated that 
the cyclolinopeptides were also able to increase fluorescence of 
porcine cyclophilin A (Fig. 4) by adding 1 |xl volumes of CLA 
to give concentrations ranging from 10 nM to 10 |tM. Fig. 4 is 
a Bjerrum plot of fractional fluorescence change against log 
concentration of CLA. Assuming a 1:1 stoichiometry of cy-
clophilin and peptide, a binding constant ^d can be estimated 
at a fractional fluorescence change of 0.5. If you assume 50% 
occupancy of cyclophilin sites, bound CLA equals unbound 
CLA, then the total concentration of CLA divided by 2 at a 
fluorescence change of 0.5 is the K&. For CLA the calculated 
Kd is 125 nM (Fig. 4). Linear CLA and MC-172 showed a 
similar response with K& values of 109 nM and 120 nM re-
spectively (not shown). In comparison CsA gave a Kd of 30 
nM, significantly lower than CLA and indicating a stronger 
affinity for cyclophilin A. Together the PPIase and tryptophan 
fluorescence studies show that CLA binds to and inhibits the 
PPIase activity of cyclophilin A. 
To determine whether CLA was able to neutralise the phos-
phatase activity of calcineurin, phosphatase assays were per-
formed. As expected CsA inhibits calcineurin phosphatase 
activity only if cyclophilin is present and FK506 inhibition 
is dependent on the presence of FKBP12 (Fig. 5). Rapamycin, 
which binds to FKBP12 to form a complex incapable of neu-
tralising calcineurin [18], is ineffective. However, CLA was 
able to inhibit dephosphorylation in the presence of cyclophi-
lin A, but not in the presence of FKBP12. In addition, CLA 
at concentrations of 5-10 u,M was able to inhibit the calci-
neurin activity of activated lymphocyte extracts (Fig. 6). Thus 
CLA, which is structurally different from CsA, is nevertheless 
also able to bind cyclophilin and inhibit calcineurin phospha-
tase activity. Nature has evolved two dissimilar naturally 
based products which have similar antibiotic and immunosup-
pressive action dependent on binding to cyclophilin. FKBP12 
cannot replace cyclophilin in either case. 
A limitation on the use of CsA is its poor solubility. The 
more soluble sulphonated peptide MC-172 inhibited T lym-
phocyte activation equally effectively and thus this change in 
the conformation of the peptide did not affect its interaction 
with either cyclophilin or calcineurin. The sulphonyl group on 
residue Phe5 of MC-172 was added to the cyclic peptide to 
improve its solubility, and studies using several different sul-
phonated CLA analogues showed this was the most immuno-
suppressive [12]. Solubility of CLA can also be improved by 
alternative substitutions [19] but their effect of these modified 
cyclic peptides on interaction with cyclophilin and calcineurin 
remains to be determined. 
It is remarkable that CLA is the third natural product 
which can target calcineurin via a PPIase. The structurally 
distinct immunosuppressant FK506 inhibits calcium-depend-
^yHT '—■ 
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Fig. 4. Bjerrum plot assessing the binding of CLA and CsA to cy-
clophilin A through enhancement of tryptophan fluorescence. The 
excitation wavelength was set at 289 nm, emission wavelength set 
between 290 and 385 nm with values being recorded at peak fluores-
cence (336 nm). Cyclophilin concentration was held at 300 nM in 
MES-NaOH pH 6.5 whilst CLA (■) and CsA ( A ) were added in 
increasing concentrations from 10 nM to 10 uM. 
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ent activation of T lymphocytes at a 1000 times lower con-
centration than CsA. In many respects its actions are similar 
to those of CsA, but it executes its activity through binding to 
FKBP12, rather than cyclophilin. CsA/cyclophilin and 
FK506/FKBP12 have quite different composite interfaces 
[20] and interact with calcineurin at slightly different sites. It 
would appear that the CLA/cyclophilin interface would share 
no obvious similarity with CsA/cyclophilin and FK506/ 
FKBP12 interfaces, though that needs to be established. The 
concept that nature has promoted three distinct natural prod-
ucts which can promote interaction between a PPIase and 
calcineurin gives substance to the idea that there might be a 
physiological interaction between PPIases and calcineurin in 
the absence of exogenous ligand. It has been claimed on the 
basis of weak interactions using the yeast two-hybrid system 
that cyclophilin and FKBP12 can interact with calcineurin in 
the absence of CsA and FK506 respectively and that addition 
of the ligands only potentiates this interaction [21]. It remains 
to be determined whether C L A is able to bind to other cyclo-
philin isoforms with the same affinity and whether these com-
plexes are able to target calcineurin with same effectiveness. 
Incubation (min) 
Fig. 6. Dephosphorylation of the calcineurin-specific peptide by acti-
vated porcine lymphocyte extracts and the effect of inhibitory pepti-
des. Lymphocytes were activated by concanavalin A for 20 min and 
extracts were prepared as stated in Section 2. Phosphorylated pep-
tide was incubated with extract diluted 1:250 in calcineurin buffer 
with the inhibitors CsA 1 |xM ( A ) , CLA at 1 |xM (▼), 5 (xM ( • ) 
and 10 U.M (■). An ethanol control was performed (o)- Dephos-
phorylation was assessed by removing 1 |xl aliquots, spotting onto 
p81 paper and quantified by liquid scintillation counting. 
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Fig. 5. Effects of PPIase and associated binding drugs on the de-
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calcineurin. The calcineurin-specific peptide was phosphorylated by 
cAMP-dependent protein kinase with [32P]ATP. Labelled peptide 
was incubated in a reaction mixture containing (A) calcineurin, por-
cine cyclophilin A, CLA 10 uM (■), CsA 1 uM ( A ) , FK506 50 nM 
( v ) and an ethanol control (o); (B) calcineurin, human FKBP12, 
CLA 10 uM (■), CsA 1 uM ( A ) , FK506 50 nM ( v ) , rapamycin 50 
nM (□) and an ethanol control (o)- Dephosphorylation was as-
sessed by removing 1 u.1 aliquots, spotting onto p81 paper and 
quantified by liquid scintillation counting. 
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